Factors that predict progression-free survival in Chinese lung adenocarcinoma patients treated with epidermal growth factor receptor tyrosine kinase inhibitors

Eitemau Tebyg

• Is there a progression‐free survival benefit of first‐line crizotinib versus standard chemotherapy and second‐line crizotinib in ALK‐positive advanced lung adenocarcinoma? A retrospective study of Chinese patients
  gan: Cui, Shaohua, et al.
  Cyhoeddwyd: (2016)
• Factors associated with efficacy of first-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer
  gan: Shaohua Cui, et al.
  Cyhoeddwyd: (2017-04-01)
• Use of capture-based next-generation sequencing to detect ALK fusion in plasma cell-free DNA of patients with non-small-cell lung cancer
  gan: Cui, Shaohua, et al.
  Cyhoeddwyd: (2016)
• Dynamics of EGFR mutations in plasma recapitulates the clinical response to EGFR-TKIs in NSCLC patients
  gan: Xiong, Liwen, et al.
  Cyhoeddwyd: (2017)
• Feasibility of continuing crizotinib therapy after RECIST-PD in advanced non-small cell lung cancer patients with ALK/ROS-1 mutations
  gan: Liu, Jun, et al.
  Cyhoeddwyd: (2018)